Tralokinumab Improves Clinically Relevant Outcome Measures: A Post Hoc Analysis of ECZTRA 3, A Randomized Clinical Trial in Patients with Moderate-To-Severe Atopic Dermatitis. J of Skin. 2020;4(6):s100. doi:10.25251/skin.4.supp.100